Pfizer re-ups CytoReason collab applying AI disease models t

Since announcing the original collaboration in January 2019, Pfizer has been using CytoReason’s machine learning technology to guide its drug development efforts, with a focus on improving the Big Pharma’s understanding of the immune system.

Related Keywords

Israel , Germany , Israeli , German , Mikael Dolsten , David Harel , Pfizer , Merck Kga , Merck Kgaa , Big Pharma , Machine Learning , Artificial Intelligence , Partnerships , Drug Development , Medtech ,